BiotechTube
Arugula Sciences

Arugula Sciences

San Diego, United States· Est.
arugulasciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Arugula Sciences is a private, clinical-stage biotech leveraging the therapeutic potential of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and acellular products. The company's lead program, Signature Cord Prime™, is in an FDA Phase 1 trial for knee osteoarthritis, with another Phase 1 study approved for big toe osteoarthritis. Founded in 2018, Arugula is pre-revenue and is building a platform around perinatal tissue biologics to treat a range of degenerative conditions, positioning itself in the competitive but high-growth cell and gene therapy sector.

OrthopedicsInflammatory DiseasesDegenerative Diseases

Technology Platform

Platform leveraging human umbilical cord-derived mesenchymal stem cells (UC-MSCs) and their acellular secretome for developing regenerative and immunomodulatory therapies.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The large and growing global market for osteoarthritis treatments, estimated in the tens of billions, presents a significant opportunity.
Success in early trials could enable expansion into other inflammatory and degenerative conditions using the same umbilical cord-derived platform, creating a pipeline of high-value biologic assets.

Risk Factors

High clinical trial risk as an early-stage company, with lead programs only in Phase 1.
Significant regulatory uncertainty surrounds the approval pathway for cell-based therapies and allografts.
The company is pre-revenue and privately funded, creating financing and dilution risk for future development.

Competitive Landscape

Arugula operates in the highly competitive orthobiologics and mesenchymal stem cell therapy space, competing against companies offering platelet-rich plasma (PRP), bone marrow aspirate concentrate, and other cell-based products for osteoarthritis. It must differentiate its UC-MSC platform on the basis of potency, manufacturing consistency, and clinical data.

More companies in Cell & Gene Therapy →More companies in United States →